Abstracts tagged "physical function"

Abstract Number: 1595 • ACR Convergence 2021
Concern About the COVID-19 Pandemic and Community Mobility Among Systemic Lupus Erythematosus Patients
Laura Plantinga¹, Courtney Hoge¹, Cristina Drenkard¹, Charmayne Dunlop-Thomas¹, Brad Pearce¹, S Sam Lim² and C. Barrett Bowling³, ¹Emory University, Atlanta, GA, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³Duke University, Durham, NC
Background/Purpose: Opportunities for community mobility, which reflects both physical mobility and social participation, during the COVID-19 pandemic have been limited and may have been related…
Abstract Number: 1613 • ACR Convergence 2021
Pandemic and Patients: Examining Health-Related Behaviors of Patients with Systemic Sclerosis During the COVID-19 Pandemic
Nancy Dorr¹, Patricia Fennell² and Lee Shapiro³, ¹The College of Saint Rose, Albany, NY, ²Albany Health Management Associates, Inc. Steffens Scleroderma Foundation, Albany, NY, ³Albany Medical College, Stillwater, NY
Background/Purpose: Prior to COVID-19, few studies examined how patients with a chronic illness, such as systemic sclerosis (SSc), react to a pandemic. This study examined…
Abstract Number: 0140 • ACR Convergence 2020
Meaningful Within-Patient Change in WOMAC Domains in Patients with Moderate-To- Severe Osteoarthritis
Philip G Conaghan¹, Robert Dworkin², Thomas Schnitzer³, Francis Berenbaum⁴, Andrew Bushmakin⁵, Joseph Cappelleri⁵, Lars Viktrup⁶ and Lucy Abraham⁷, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Sorbonne Universite�, Paris, France, ⁵Pfizer Inc, Groton, CT, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Tadworth, United Kingdom
Background/Purpose: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a disease-specific measure of osteoarthritis (OA) symptoms (pain and stiffness) and functional impairment regularly…
Abstract Number: 1650 • ACR Convergence 2020
A Double-Blind Randomized Trial to Evaluate the Efficacy of Corticosteroid Injections for Osteoarthritis of the Knee Using Mobile Devices
Joshua Baker¹, Mitesh Patel¹, Tuhina Neogi², Keith Robinson³, Alexis Ogdie¹ and Carla Scanzello¹, ¹University of Pennsylvania, Philadelphia, PA, ²Boston University School of Medicine, Boston, MA, ³Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: The value of intra-articular (IA) corticosteroid injections for osteoarthritis of the knee (KOA) has recently been called into question. Variability in clinical trial design…
Abstract Number: 0322 • ACR Convergence 2020
Development and Preliminary Validation of Smartphone Sensor-based Measurement Tools for Psoriatic Arthritis
Dan Webster¹, Rebecca Haberman², Lourdes Perez-Chada³, Stockard Simon⁴, Woody MacDuffie⁴, Michael DePhillips⁵, Soumya Reddy⁶, Alexis Ogdie⁷, Lara Mangravite⁴, Joseph Merola⁸ and Jose Scher², ¹Sage Bionetworks, Seattle, WA, ²NYU School of Medicine, New York City, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Sage Bionetworks, Seattle, ⁵SDP Digital, Seattle, ⁶NYU School of Medicine, New York, NY, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: The COVID-19 pandemic has increasingly driven clinical care into remote settings, where patients with immune-mediated and inflammatory diseases struggle to convey symptom severity to…
Abstract Number: 1728 • ACR Convergence 2020
Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study
Martin Bergman¹, Jeffrey Enejosa², Naomi Martin², Jessica Suboticki², Debbie Goldschmidt³, Yan Song³ and Namita Tundia², ¹Drexel University College of Medicine, Philadelphia, PA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA
Background/Purpose: In patients with active rheumatoid arthritis (RA), treatment with upadacitinib (UPA) has resulted in clinically meaningful improvements in patient-reported outcomes (PROs). This post hoc…
Abstract Number: 0337 • ACR Convergence 2020
Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function
Anna-Maria Liphardt¹, Eva Manger², Sonja Liehr², Lisa Bieniek², Arnd Kleyer³, David Simon³, Koray Tascilar³, Michael Sticherling⁴, Juergen Rech³, Georg Schett⁵ and Axel Hueber⁶, ¹Friedrich-Alexander-University Erlangen-Nuremberg, Internal Medicine 3 - Rheumatology & Immunology, University Hospital Erlangen, Erlangen, Bayern, Germany, ²Departement of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ³Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁶Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany
Background/Purpose: To compare the impact of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) on objective and subjective parameters of hand function.Methods: Hand function was assessed…
Abstract Number: 0536 • ACR Convergence 2020
Systematic Geriatric Assessment in Older Patients with Rheumatic Diseases – The RheuMAGIC Pilot Study
Bjoern Buehring¹, Anna Berrisch², Ioana Andreica³, Styliani Tsiami⁴, David Kiefer³, Uta Kiltz², Xenofon Baraliakos² and Juergen Braun², ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Velbert, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Current demographic data predict that the number of older adults with rheumatic diseases will considerably increase in the coming years. Geriatric patients differ from…
Abstract Number: 0551 • ACR Convergence 2020
Physical Performance as a Mediator of the Association Between Depression and Pain in Knee Osteoarthritis
Alan Rathbun¹, Elizabeth Stuart², Michelle Shardell¹, Trang Nguyen², Alice Ryan¹, Joseph Gallo², Michelle Yau³, Megan Schuler⁴ and Marc Hochberg¹, ¹University of Maryland School of Medicine, Baltimore, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³Hinda and Arthur Marcus Institute for Aging Research, Boston, MA, ⁴RAND Corporation, Boston, MA
Background/Purpose: Depression is common in knee osteoarthritis (OA), and leads to reduced physical function, which may mediate the effect of depression on pain. However, research…
Abstract Number: 0744 • ACR Convergence 2020
Circulating Fibroblast Growth Factor-21 Levels in Rheumatoid Arthritis: Associations with Disease Characteristics, Body Composition, and Physical Functioning
Patrick Gould¹, Babette Zemel², Elena Taratuta³ and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³University of Pennsylvania, Philadelphia
Background/Purpose: Rheumatoid arthritis (RA) can lead to changes in body composition, including muscle loss and excess adiposity, which are in turn associated with physical disability.…
Abstract Number: 0931 • ACR Convergence 2020
Oropharyngeal Dysfunction in Patients with Systemic Sclerosis – Results of a Monocentric Clinical Study
Philipp Klemm¹, Mirjam Wirths², Ole Hudowenz², Ulrike Hoffmann³, Ulf Müller-Ladner² and Uwe Lange², ¹Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Hessen, Germany, ²Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ³Practice for Speech Therapy Ulrike Hoffmann, Friedberg, Germany
Background/Purpose: Nearly 98% of patients with systemic sclerosis (SSc) are suffering from gastrointestinal involvement (Schmeiser et al. 2012). While in everyday clinical practice screening for…
Abstract Number: 1084 • ACR Convergence 2020
Consumer-based Activity Trackers in Evaluation of Physical Function in Myositis Patients
Didem Saygin¹, Bonny Rockette-Wagner², Chester Oddis³, Diane Koontz¹, Siamak Moghadam-Kia¹ and Rohit Aggarwal², ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies are systemic inflammatory conditions characterized by muscle weakness and reduced muscle endurance that limit activities of daily living. Daily step count…
Abstract Number: 1110 • ACR Convergence 2020
Osteoarthritis-Related Knee Inflammation Measured by Ultrasound Is Associated with Performance-Based Measures of Function
Holly Philpott¹, Trevor Birmingham², Ryan Pinto², Dominique Arsenault², Codie Primeau², Edward Vasarhelyi³, Steven MacDonald³, Brent Lanting³ and Tom Appleton⁴, ¹Western University, London, ON, Canada, ²Western University, London, Canada, ³London Health Sciences Centre, London, Canada, ⁴The University of Western Ontario, LONDON, ON, Canada
Background/Purpose: Signs of inflammation in knee osteoarthritis (OA), including synovitis, are associated with worse clinical outcomes such as increased pain, risk of progression, and future…
Abstract Number: 1341 • ACR Convergence 2020
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study
Vibeke Strand¹, Philip Mease², Enrique Soriano³, Mitsumasa Kishimoto⁴, Carlo Salvarani⁵, Nemanja Damjanov⁶, Jaclyn K Anderson⁷, Erin Blondell⁷, Patrick Zueger⁷, Christopher Saffore⁷ and Dafna Gladman⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina, ⁴Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, ⁵Rheumatology Units, University of Modena and Reggio Emilia, and Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy, ⁶University of Belgrade Medical School, Belgrade, Serbia, ⁷AbbVie Inc., North Chicago, IL, ⁸Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patient-reported outcomes (PROs) are important when evaluating treatment benefits in PsA. We present an analysis of PRO data from the SELECT-PsA 1 study.Methods: SELECT-PsA…
Abstract Number: 1371 • ACR Convergence 2020
Improvement in Patient-Reported Outcomes for Upadacitinib versus Placebo Among Patients with Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs
Vibeke Strand¹, Filip Van den Bosch², Roberto Ranza³, Ying Ying Leung⁴, Edit Drescher⁵, Apinya Lertratanakul⁶, Ralph Lippe⁷, Christopher Saffore⁶, Patrick Zueger⁶ and Peter Nash⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Ghent University Hospital, Ghent, Belgium, ³Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁴Department of Rheumatology & Immunology, Singapore General Hospital, Singapore, Singapore, ⁵Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: The efficacy and safety of upadacitinib (UPA), a selective Janus kinase inhibitor, in patients with PsA is under investigation in Phase 3 clinical trials.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].